Health Condition 1: null- Patients with Epithelial Ovarian Carcinoma Who Have Failed Platinum-Based Chemotherapy
Conditions
Interventions
Intervention1: Generic Formulation of Doxorubicin Hydrochloride (HCl) Liposome
Injection â?? TOLMAR formulation
: A standardized dose of 50 mg/m2 of TOLMAR formulation or DOXOrubicin will be administe
Sponsors
TOLMAR Inc
Eligibility
Inclusion criteria
Inclusion criteria: 1. Female between 18 and 75 years of age, inclusive. 2. Histologically proven epithelial ovarian carcinoma. 3. Documented progressive or recurrent disease after treatment with platinum based chemotherapy. 4. Able and clinically indicated to receive liposomal doxorubicin HCl, as specified in the DOXOrubicin Package Insert for subjects with ovarian cancer, without exceeding a lifetime cumulative dosage of 450 mg/m2 (See Section 7.3.1 for rationale). Prior use of conventional or liposomal doxorubicin formulations, in addition to the use of other anthracyclines or anthracenediones should be included in calculations of total lifetime cumulative dose. 5. Able and clinically indicated to receive the recommended minimum 4 courses of liposomal doxorubicin HCl either during participation in this study, including infusions prior to enrolling in this study or after completing study participation 6. Eastern Cooperative Oncology Group (ECOG) performance status of 7. Life expectancy of > 180 days. 8. Acceptable hematology status: a. Hemoglobin >= 9 g/dL b. Absolute neutrophil count (ANC) >= 1500 cells/µL c. Platelet count >= 75,000 cells/µL 9. Acceptable liver function: a. Alanine aminotransferase (ALT) b. Aspartate aminotransferase (AST) c. Bilirubin d. Alkaline phosphatase 10. Acceptable kidney function a. Creatinine b. Creatinine clearance >= 60 mL/minute 11. Cardiac ejection fraction >= 50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within 14 days prior to first dose of Investigational Product. 12. If of childbearing potential, must agree to use adequate contraception (eg, hormonal, chemical, double-barrier, or abstinence) while on study and for 3 months after study participation is discontinued. 13. Willing and able to provide written informed consent prior to any study-related activities being performed.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. Received liposomal doxorubicin HCl in the past and had a required dose reduction to below 50 mg/m2, or whose disease has progressed or recurred after treatment with liposomal doxorubicin. 2. Received previous chemotherapy less than 4 weeks prior to dosing of Investigational Product. 3. Recent (6 month) history of myocardial infarction or severe arrhythmias prior to dosing of Investigational Product (See DOXOrubicin Package Insert). 4. History of major cardiac (New York Heart Association [NYHA] Type III or IV), liver, or kidney disease. 5. Received any prior mediastinal irradiation (as cardiac toxicity may occur at lower cumulative doses). 6. Receipt of trastuzumab within 24 weeks prior to dosing of Investigational Product and during the study (DOXOrubicin Hydrochloride Injection Package Insert). 7. Receipt of cyclophosphamide, calcium channel blockers, and other potential cardiotoxic drugs for 2 weeks prior to dosing of Investigational Product, and during the study (See DOXOrubicin Package Insert and anthracycline package insert). 8. Receipt of phenytoin for 2 weeks prior to dosing of Investigational Product, and during the study as phenytoin levels may be decreased by doxorubicin (See DOXOrubicin Hydrochloride Injection Package Insert). 9. Known hypersensitivity, idiosyncratic, or allergic reactions to conventional or liposomal formulations of doxorubicin, anthracycline therapy or to any of their components. 10. Pregnant or breastfeeding. 11. Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganism. 12. Presence or recent history (within the last 2 months) of clinically significant ascites requiring intervention (eg, paracentesis). Note: stable dose of diuretics will be permitted. 13. Known central nervous system metastasis. 14. Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product. 15. Surgical or other non-healing wounds. 16. Exposure to any investigational agent within 28 days prior to first dose of Investigational Product. 17. History of other malignancies in the last 5 years. Potential subjects with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Potential subjects with other malignancies that were cured with definitive primary therapy alone (eg, surgery) and who have been continuously free of the previous disease for 1 year are also eligible upon Sponsor approval. 18. Severe or life-threatening infection, including known past medical history of human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). 19. Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], v4.03). 20. Uncontrolled diabetes mellitus. 21. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requir
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the PK parameters of DOXOrubicin and TOLMAR formulation in subjects with progressive or recurrent epithelial ovarian cancer. Timepoint: Up to 30 minutes prior dosing, During infusion: 0.50 hr; end of infusion: 1.00 hr and after end of infusion: 2.00, 3.00, 4.00, 8.00, 24.00, 48.00, 96.00, 168.00, 240.00, 336.00 hr | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess safety and tolerability of DOXOrubicin and TOLMAR Formulation. Timepoint: NA | — |
Countries
Australia, India, Malaysia, Mexico, New Zealand, Thailand, United States of America
Contacts
Public ContactDr Bina Naik
CBCC-Vibgyor Research Pvt. Ltd.
Outcome results
None listed